Anavex Life Sciences Corp (OTCMKTS:AVXL) successfully grabbed the attention at the ‘12th International Conference on Alzheimer’s’ as well as ‘Parkinson’s Diseases and Related Neurological Disorders’ conference held in France. The clinical stage biopharma company reported promising preclinical data for its two drugs, namely ‘ANAVEX 2-73’ and ‘ANAVEX 3-71’ (previously known as AF710B).
Two positive pre-clinical tests
While presenting at the 12th International Conference, Tangui Maurice, PhD and on the Advisory board of the Anavex Life Sciences Corp (OTCMKTS:AVXL) showed the important role played by sigma-1 receptor (S1R) on memory and survival. He showed that the genetic dormancy of the S1R gene negatively impacts amyloid toxicity and also dampens its survival and impact on memory impairment. It is to be noted that Amyloid is blamed for the development of Alzheimer’s disease (AD). The company demonstrated that by targeting the S1R, which is a key element in brain plasticity, neuro safety in Alzheimer’s disease could be enhanced. Anavex Life Sciences Corp (OTCMKTS:AVXL) said that ANAVEX 2-73 is presently under a Phase 2a studyfor its efficacy and effectiveness in Alzheimer’s patients.
Separately, Anavex Life Sciences Corp (OTCMKTS:AVXL) presented the pre-clinical data of ANAVEX 3-71 as it showed that it rescued spine loss or mushroom synaptic in hippocampal neurons of wild-type. The company outlined evidence that showed that ANAVEX 3-71 also reduced both soluble and insoluble plaques and decreased BACE1 expression. Thus, the results are encouraging to point out that ANAVEX 3-71 has the potential to treat Alzheimer’s and other protein-aggregated related diseases.
Future development
Anavex Life Sciences Corp (OTCMKTS:AVXL)’s President and CEO, Christopher U. Missling, Ph.D., said that the company will update about the progress on ANAVEX 2-73 next quarter. He added that it will positively take the development of ANAVEX 3-71 to next stage.
Anavex Life Sciences Corp (OTCMKTS:AVXL) closed at $0.21 in its last trading session and recorded an average volume of 537.031 shares.
